Aldo-keto reductase 1B10 (AKR1B10) is upregulated in breast cancer and promotes tumor growth and metastasis. However, little is known of the molecular mechanisms of action.
various pathophysiological processes. [1] [2] [3] Fatty acids are essential components of various lipids, such as triglycerides and phosphoglycerides. Lipogenesis is increased in tumors and contributes to various aspects of tumorigenesis and progression, such as cell proliferation, differentiation, and invasion. 1, 4 The high proliferation of cancer cells depends on lipid synthesis to meet both the needs of biomembrane synthesis in cell division and function as signal molecules, stimulating cell growth and proliferation. 5 and activates protein kinase C (PKC). [5] [6] [7] PKC is an important oncogenic kinase that activates ERK1/2 signaling to promote cancer growth and progression. 8, 9 The phosphorylation-activated ERK1/2 translocates into the nucleus where it phosphorylates and activates MSK, p90RSK, and transcription factors (eg, c-Myc, Elk-1, and Ets-1) to stimulate cell growth and proliferation. 10 Therefore, lipid second messengers are important cellular signal molecules that regulate cell growth, proliferation, and survival. Interestingly, this study found that aldoketo reductase 1B10 is a novel regulator of intracellular lipid messengers.
Aldo-keto reductase 1B10 (AKR1B10), also referred as aldose reductase-like-1 (ARL-1), 11 is a monomeric enzyme with strong catalytic activity to α, β-unsaturated carbonyl compounds [12] [13] [14] and protects the host cells from carbonyl lesions. [15] [16] [17] This has important biological significance as the human beings are constantly exposed to the carbonyls derived from daily diet consumption, microbes inhabited within digestive tract, cellular metabolism and lipid peroxidation in oxidative stress. [18] [19] [20] [21] As a carbonyl reductase, AKR1B10 also works as an efficient retinal reduction enzyme to convert retinals to retinols, thus mediating homeostasis of retinoid acid and cell differentiation. 22, 23 AKR1B10 also mediates cancer cell sensitivity to anthracyclines. 24, 25 More importantly, AKR1B10 is a mediator of long chain fatty acid synthesis. AKR1B10 associates with acetyl-CoA carboxylase-α (ACCA) and prevents its ubiquitin-dependent degradation. 26 ACCA is a ratelimiting enzyme in de novo fatty acid synthesis, and thus AKR1B10 Acini were photographed by a phase contrast microscopy (Carl Zeiss, Thornwood, NY).
| AKR1B10 ectopic expression and silencing
Full-length AKR1B10 cDNA was inserted into pCDH lentiviral expression vector with a GFP reporter (System Biosciences, Palo
Alto, CA). After packaging in 293T cells, AKR1B10 and empty pCDH lentiviral particles were introduced into cells with standard procedures.
GFP-labeled cells were sorted for a homogeneous population.
Scrambled and AKR1B10 siRNAs were chemically synthesized (Ambion, Austin, TX) and delivered into cells as previously described. 37 Two siRNAs that target encoding (siRNA 1: 5′ GCAAGUUGUGGCCCACUUUtt) and 3′ untranslational (siRNA 2: 5′ CGAGAAUCGAGGUGCUGUUtt) regions of AKR1B10 were used for silencing. A scrambled siRNA with random RNA sequences was used as a control.
AKR1B10 knockdown was examined using Western blot. 
| Growth rate

| Western blot
Protein lysates, SDS-PAGE, and Western blotting were performed as previously described. Ultra triple quadrupole mass spectrometer operated in SRM mode under ESI(+). Data processing was conducted with X calibur (Thermo).
| LC-MS analyzes of diacylglycerol
Quality control (QC) samples were prepared by pooling the aliquots of study samples and were used to monitor instrument stability. The QC was injected seven times at the beginning to stabilize the instrument, and was injected again every five study samples. Only the lipid species with CV < 15% in QC sample were reported. Relative quantification of lipids was provided, and data were reported as the peak area ratios of the analytes to the internal standard. Relative quantification data generated in same batches are appropriate to compare the change of an analyte in AKR1B10 expression or AKR1B10 silencing samples to the corresponding control. 
| Statistical analysis
Statistical analyses were performed using Student's t tests or ANOVA with INSTAT statistical analysis package (Graph Pad software, La Jolla, CA). Significance was defined as P < 0.05. Correlation analyses were conducted using Spearman correlation and multivariate canonical correlation. 
| PKC/ERK signaling cascade is activated by AKR1B10 in breast cancer cells
DAG is an activator of protein kinase C (PKC) family members. 9 Therefore, we examined phosphorylation activation of PKC Figure 5B ). These data suggest that the ERK1/2 signaling activated by AKR1B10 promotes cell growth and proliferation through the targets p90RSK, MSK, and cyclin D1 in the breast cancer cells.
| AKR1B10 promotes growth of MCF-7 tumor xenografts in female nude mice
To confirm the cancer-promoting role of AKR1B10, we further evaluated its effects on growth of tumor xenografts in vivo.
Luciferase-labeled MCF-7 cells with targeted AKR1B10 expression or a vector control were injected subcutaneously into the mammary fat pads of female nude mice (n = 5 per group). Tumor volume was monitored by both in vivo imaging and caliper measurements. As shown in Figure 6 , MCF-7 tumors with AKR1B10 expression grew faster than vector control tumors. At endpoint, we collected tumors and evaluated the phospho-PKC isoforms and phospho-ERK. As shown in Figure 6D , the PKC/ERK signaling pathway was activated by AKR1B10 in tumors. These data suggest that AKR1B10 promotes breast cancer growth in vivo by activating the PKC/ERK signaling pathway, being an oncogenic protein in breast cancer growth and progression. It is noteworthy to note that AKR1B10 can promote cell survival through protection from reactive carbonyl lesions. 13, 17, 37 Although repetitive observations were not conducted in these breast cancer cells with targeted expression or silencing of AKR1B10, we believe that the carbonyl detoxification mechanism of AKR1B10 may also contribute to the cell growth and proliferation.
In summary, this study obtained a series of data that mechanistically address the oncogenic role of AKR1B10 in growth and progression of breast cancer. AKR1B10 promotes lipogenesis and enhances cellular PIP2, DAG, and IP3 levels. These lipid second messengers activate PKC and thus the PKC-mediated ERK signaling cascade, promoting growth and proliferation of breast cancer cells ( Figure 7 ). AKR1B10 is a novel oncogenic protein in breast cancer.
FIGURE 7
Hypothetic model of cell growth and proliferation promoted by AKR1B10. In the breast cancer cells, AKR1B10 promotes lipogenesis and increases cellular lipid second messengers PIP2, IP3, and DAG, which activates the PKC/ERK signaling cascade. The p90RSK, MSK, and cyclin D1 functions as downstream targets of the ERK1/2 in this process
